Schiff
New Move Free Advanced contains Uniflex and hyaluronic acid, "which make the product two times more effective in relieving joint pain compared to triple strength glucosamine and chondroitin alone," Schiff Nutrition International announces Jan. 25. Uniflex is a dual bioflavanoid antioxidant system, which protects against the breakdown of cartilage and joint tissues, and helps keep joints working better. The new SKU "works in as little as seven to 14 days, versus four to eight weeks for products containing glucosamine and chondroitin alone" the firm claims, and is backed by an independent study conducted in 2004. Move Free Advanced and Move Free Advanced Plus are available now at health, food, drug and mass merchandisers nationwide, Schiff says...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.